REFERENCES
- Petzer AL, Gunsilius E, Hayes, Stockhammer G, Duba HCH, Schneller F, Grfinewald K, Poewe W, Gastl G. Low concentrations of STI571 in the cerebrospinal fluid: a case report. Br J Haematol 2002;117: 623— 625.
- Pfeifer H, Wassmann B, Hofmann W-K, Komor M, Scheuring U, Brack P, Binckebanck A, Schleyer E, Gokbuget N, Wolff T. Risk and prognosis of central nervous system leukemia in patients with Philadelphia chromosome-positive acute leuke-mias treated with imatinib. Chin Cancer Res 2003;9:4674 — 4681.
- Bornhauser M, Jenke A, Freiberg-Richter J, Radke J, Schuler US, Mohr B, Ehringer G, Schleyer E. CNS blast crisis of chronic myelogenous leukemia in a patient with a major cytogenetic response in bone marrow associated with low levels of imatinib mesylate and its N-desmethylated metabolite in cerebral spinal fluid. Ann Hematol 2004;83:401— 402.
- Hasford J, Pfirrmann M, Hehlmann R, Allan NC, Baccarani M, Kluin-Nelemans JC, Alimena G, Steegman JL, Ansani H. A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alpha. J Natl Cancer Inst 1998;90:850— 858.
- Larson R, Dodge R, Linker CA, Stone RM, Powell BL, Lee EJ, Schulman P, Davey FR, Frankel SR, Bloomfield CD, A randomized controlled trial of filgrastim during remission induction and consolidation chemotherapy for adults with acute lymphoblastic leukemia: CALGB Study 9111. Blood 1998;92:1556— 1564.
- Dai H, Marbach P, Lemaire M, Hayes M, Elmquist W. Distribution of STI-571 to the brain is limited by P-glycoprotein-mediated efflux. J Pharmacol Exp Ther 2003; 304:1085–1092.
- Wolff NC, Richardson JA, Egorin M, Ilaria R The CNS is a sanctuary for leukemic cells in mice receiving imatinib mesylate (STI 571) for BCR/Abl- induced leukemia. Blood 2003;101:5010–5013.